(NASDAQ: SBFM) Sunshine Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 41,140.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,999.5%.
Sunshine Biopharma's earnings in 2025 is -$5,992,637.On average, 3 Wall Street analysts forecast SBFM's earnings for 2025 to be -$5,054,105, with the lowest SBFM earnings forecast at -$4,855,904, and the highest SBFM earnings forecast at -$5,202,755.
In 2026, SBFM is forecast to generate -$1,601,300 in earnings, with the lowest earnings forecast at -$1,538,504 and the highest earnings forecast at -$1,648,398.